Biogen’s Tecfidera MS Drug Wins EU Agency’s Backing

Biogen Idec Inc. won European Union backing for Tecfidera, one of the first therapies for multiple sclerosis available in an easy-to-take pill that analysts say may generate $3.25 billion in annual sales.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.